Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Maziarz, Richard T., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, Tam, Constantine S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Immunobiology and Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042998/
https://ncbi.nlm.nih.gov/pubmed/32074277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001026
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi